These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22911331)

  • 41. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer.
    Cole SR; Young GP; Esterman A; Cadd B; Morcom J
    J Med Screen; 2003; 10(3):117-22. PubMed ID: 14561262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.
    Zauber AG; Lansdorp-Vogelaar I; Knudsen AB; Wilschut J; van Ballegooijen M; Kuntz KM
    Ann Intern Med; 2008 Nov; 149(9):659-69. PubMed ID: 18838717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
    Saito H; Soma Y; Nakajima M; Koeda J; Kawaguchi H; Kakizaki R; Chiba R; Aisawa T; Munakata A
    Oncol Rep; 2000; 7(4):815-9. PubMed ID: 10854550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patterns of occult bleeding in asymptomatic colorectal cancer.
    Ahlquist DA; McGill DB; Fleming JL; Schwartz S; Wieand HS; Rubin J; Moertel CG
    Cancer; 1989 May; 63(9):1826-30. PubMed ID: 2702590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparative study of eight fecal occult blood tests and HemoQuant in patients in whom colonoscopy is indicated.
    Gopalswamy N; Stelling HP; Markert RJ; Maimon HN; Wahlen SD; Haddy RI
    Arch Fam Med; 1994 Dec; 3(12):1043-8. PubMed ID: 7804488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review article: faecal occult blood testing for colorectal cancer.
    Allison JE
    Aliment Pharmacol Ther; 1998 Jan; 12(1):1-10. PubMed ID: 9692694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas.
    Macrae FA; St John DJ
    Gastroenterology; 1982 May; 82(5 Pt 1):891-8. PubMed ID: 7060910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia.
    Hope RL; Chu G; Hope AH; Newcombe RG; Gillespie PE; Williams SJ
    Gut; 1996 Nov; 39(5):722-5. PubMed ID: 9014773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials.
    Lansdorp-Vogelaar I; van Ballegooijen M; Boer R; Zauber A; Habbema JD
    Cancer; 2009 Jun; 115(11):2410-9. PubMed ID: 19288570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.
    Towler B; Irwig L; Glasziou P; Kewenter J; Weller D; Silagy C
    BMJ; 1998 Aug; 317(7158):559-65. PubMed ID: 9721111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.
    Young GP; St John DJ; Winawer SJ; Rozen P;
    Am J Gastroenterol; 2002 Oct; 97(10):2499-507. PubMed ID: 12385430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.
    Castiglione G; Zappa M; Grazzini G; Mazzotta A; Biagini M; Salvadori P; Ciatto S
    Br J Cancer; 1996 Jul; 74(1):141-4. PubMed ID: 8679448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable.
    Sinatra MA; St John DJ; Young GP
    Clin Chem; 1999 Jan; 45(1):123-6. PubMed ID: 9895348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemoccult sensitivity estimate in a screening program for colorectal cancer in the Province of Florence.
    Castiglione G; Grazzini G; Poli A; Bonardi R; Ciatto S
    Tumori; 1991 Jun; 77(3):243-5. PubMed ID: 1862554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interval cancers in screening with fecal occult blood test for colorectal cancer.
    Jensen BM; Kronborg O; Fenger C
    Scand J Gastroenterol; 1992 Sep; 27(9):779-82. PubMed ID: 1411286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of the Hemoccult Test in the detection of colorectal cancer].
    Janković S; Kostić Z; Marinković J; Radovanović Z
    Vojnosanit Pregl; 1994; 51(3):220-3. PubMed ID: 8560835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of the 'directions for use' on positivity rates of the Hemoccult II test.
    Faure H; Exbrayat C; Garnier A; Dumas P; Winckel P; Bolla M
    Eur J Gastroenterol Hepatol; 1998 Dec; 10(12):1021-4. PubMed ID: 9895048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling.
    Niedermaier T; Weigl K; Hoffmeister M; Brenner H
    Eur J Epidemiol; 2017 Jun; 32(6):481-493. PubMed ID: 28667446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.